Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: This panel will focus on how the use of novel approaches such as liquid biopsies and technologies such as NGS can be integrated in personalized medicine to improve patient management. We will discuss what it will take for the most recent developments to be incorporated in routine clinical care.
Session Chair Profile
Ph.D., Partner, DeciBio Consulting
Dr. Stephane Budel is a partner at DeciBio Consulting with over 18 years of combined experience in life science business consulting, entrepreneurship and academic research. He specializes in helping companies commercialize novel and disruptive technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to the impact of next generation sequencing. He has supported clients facing a broad range of challenging business issues, including product specification strategy and commercial due diligence. Dr. Budel earned his Ph.D. from Yale University for his research on the molecular mechanisms of schizophrenia.
M.D., VP of Clinical Development, GRAIL, Inc.
Anne-Renee Hartman is the Vice President of Clinical Development at GRAIL, Inc. where she is responsible for the design and execution of clinical programs to discover and validate cell-free nucleic acid technology for early detection of cancer. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, Inc. At Myriad, Anne-Renee led the development of several commercialized diagnostics in oncology, including hereditary cancer testing, companion diagnostics for PARP therapy, and diagnostic and prognostic assays for melanoma, lung, and prostate cancer. Anne-Renee was previously an Assistant Professor of Medicine at The Dana-Farber Cancer Institute, specializing in breast cancer genetics. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a Bachelor’s degree in Molecular Biology from Princeton University, an M.D. from the University of Michigan, and completed her residency in Internal Medicine at the University of Chicago.
Ph.D., Professor & Chair, Stanford Center of Genomics & Personalized Medicine
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome.
Ph.D., Co-Founder & Head of Illumina Accelerator
Amanda Cashin is Co-Founder and Head of Illumina Accelerator, a leading company creation engine and investment vehicle focused on building genomics-driven startups. Founded in Fall 2014 in San Francisco, Illumina Accelerator has invested in over 10 startups advancing breakthrough applications in genomics, including applications in therapeutics, women’s health, cancer diagnostics, consumer nutrition, agriculture, synthetic biology, and skin microbiome. Previously, Amanda was Senior Vice President of Alexandria Venture Investments at Alexandria Real Estate Equities, Inc. Amanda also led a team of life science professionals with strong science and business expertise responsible for industry research, company analysis, business development, and thought leadership activities to help position Alexandria at the forefront of the industry. She earned a Ph.D. in Chemical Biology from the California Institute of Technology. Her scientific expertise and peer-reviewed publications are in the fields of biochemistry, organic chemistry, physical chemistry, pharmacology, electrophysiology, and neuroscience.